These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 31122207)
1. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer. Rutkovsky AC; Yeh ES; Guest ST; Findlay VJ; Muise-Helmericks RC; Armeson K; Ethier SP BMC Cancer; 2019 May; 19(1):491. PubMed ID: 31122207 [TBL] [Abstract][Full Text] [Related]
2. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Karlsson E; Waltersson MA; Bostner J; Pérez-Tenorio G; Olsson B; Hallbeck AL; Stål O Genes Chromosomes Cancer; 2011 Oct; 50(10):775-87. PubMed ID: 21748818 [TBL] [Abstract][Full Text] [Related]
3. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Karlsson E; Pérez-Tenorio G; Amin R; Bostner J; Skoog L; Fornander T; Sgroi DC; Nordenskjöld B; Hallbeck AL; Stål O Breast Cancer Res; 2013; 15(5):R96. PubMed ID: 24131622 [TBL] [Abstract][Full Text] [Related]
4. KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer. Turner-Ivey B; Guest ST; Irish JC; Kappler CS; Garrett-Mayer E; Wilson RC; Ethier SP Neoplasia; 2014 Aug; 16(8):644-55. PubMed ID: 25220592 [TBL] [Abstract][Full Text] [Related]
5. 8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy. Voutsadakis IA J Clin Med; 2020 Sep; 9(10):. PubMed ID: 32987805 [TBL] [Abstract][Full Text] [Related]
6. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Pourdehnad M; Truitt ML; Siddiqi IN; Ducker GS; Shokat KM; Ruggero D Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11988-93. PubMed ID: 23803853 [TBL] [Abstract][Full Text] [Related]
7. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559 [TBL] [Abstract][Full Text] [Related]
8. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Rojo F; Najera L; Lirola J; Jiménez J; Guzmán M; Sabadell MD; Baselga J; Ramon y Cajal S Clin Cancer Res; 2007 Jan; 13(1):81-9. PubMed ID: 17200342 [TBL] [Abstract][Full Text] [Related]
9. Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Satheesha S; Cookson VJ; Coleman LJ; Ingram N; Madhok B; Hanby AM; Suleman CA; Sabine VS; Macaskill EJ; Bartlett JM; Dixon JM; McElwaine JN; Hughes TA Mol Cancer; 2011 Feb; 10():19. PubMed ID: 21320304 [TBL] [Abstract][Full Text] [Related]
10. Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells. Ochnik AM; Peterson MS; Avdulov SV; Oh AS; Bitterman PB; Yee D Neoplasia; 2016 Feb; 18(2):100-10. PubMed ID: 26936396 [TBL] [Abstract][Full Text] [Related]
11. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice. Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583 [TBL] [Abstract][Full Text] [Related]
12. Transforming function of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon. Streicher KL; Yang ZQ; Draghici S; Ethier SP Oncogene; 2007 Mar; 26(14):2104-14. PubMed ID: 17001308 [TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512 [TBL] [Abstract][Full Text] [Related]
14. Genomic organization of the 8p11-p12 amplicon in three breast cancer cell lines. Yang ZQ; Albertson D; Ethier SP Cancer Genet Cytogenet; 2004 Nov; 155(1):57-62. PubMed ID: 15527903 [TBL] [Abstract][Full Text] [Related]
15. The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer. Ding M; Van der Kwast TH; Vellanki RN; Foltz WD; McKee TD; Sonenberg N; Pandolfi PP; Koritzinsky M; Wouters BG Mol Cancer Res; 2018 Apr; 16(4):682-695. PubMed ID: 29453322 [TBL] [Abstract][Full Text] [Related]
16. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206. Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation. George A; Panda S; Kudmulwar D; Chhatbar SP; Nayak SC; Krishnan HH J Biol Chem; 2012 Feb; 287(7):5042-58. PubMed ID: 22184107 [TBL] [Abstract][Full Text] [Related]
18. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Garcia MJ; Pole JC; Chin SF; Teschendorff A; Naderi A; Ozdag H; Vias M; Kranjac T; Subkhankulova T; Paish C; Ellis I; Brenton JD; Edwards PA; Caldas C Oncogene; 2005 Aug; 24(33):5235-45. PubMed ID: 15897872 [TBL] [Abstract][Full Text] [Related]
19. Protein phosphatase PPM1G regulates protein translation and cell growth by dephosphorylating 4E binding protein 1 (4E-BP1). Liu J; Stevens PD; Eshleman NE; Gao T J Biol Chem; 2013 Aug; 288(32):23225-33. PubMed ID: 23814053 [TBL] [Abstract][Full Text] [Related]
20. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer. Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]